[New Horizons for the Use of Valsartan + Sacubitril in Heart Failure Patients with Hypertension]

Related Experiment Video

Updated: Jan 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.0K

V N Larina1, V G Larin1

  • 1Pirogov Russian National Research Medical University.

Kardiologiia
|December 29, 2025
PubMed

Insights

New combination therapy with valsartan and sacubitril is recommended for managing chronic heart failure (CHF) and arterial hypertension (AH). This treatment improves survival and reduces hospitalizations in patients with CHF and reduced left ventricular ejection fraction (LVEF).

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) and arterial hypertension (AH) represent a significant and growing global health burden.
  • Effective secondary prevention strategies are crucial, necessitating the integration of recent therapeutic advancements.
  • The combination of valsartan and sacubitril has emerged as a key therapeutic option since 2015.

Purpose of the Study:

  • To discuss current advances in combination therapy for multimorbid patients with CHF and AH.
  • To evaluate the efficacy, tolerability, and safety of valsartan + sacubitril in achieving target blood pressure.
  • To assess the reduction in cardiovascular complications associated with this combination therapy.

Main Methods:

  • Review of current literature and clinical guidelines on valsartan + sacubitril therapy.
  • Analysis of studies investigating the impact of valsartan + sacubitril on prognosis in CHF patients with reduced left ventricular ejection fraction (LVEF).
  • Exploration of expanded indications for valsartan + sacubitril in essential AH and CHF with any LVEF.

Main Results:

  • Valsartan + sacubitril is recommended for CHF patients with reduced LVEF, showing positive prognostic effects.
  • Expanded indications now include essential AH and CHF with any LVEF, aiming to improve survival and reduce hospitalizations.
  • The combination therapy aids in achieving target blood pressure and mitigating cardiovascular risks.

Conclusions:

  • Valsartan + sacubitril represents a significant advancement in managing patients with CHF and AH.
  • This combination therapy offers improved survival rates and decreased hospitalization frequency.
  • The drug combination demonstrates a favorable safety and tolerability profile for multimorbid patients.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
727
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233